A Promising New Longevity Supplement Shows Potential in Clinical Trials
A Swiss biotech company, Amazentis SA, is making waves in the longevity supplement market with their latest clinical trial results showing promising outcomes. The company has been testing an oral antioxidant supplement that aims to alter immune aging, and initial findings are encouraging.
According to researchers at Amazentis SA and an international team of scientists, the supplement has been well-tolerated and deemed safe for daily use. The latest clinical trial also indicates potential benefits for rejuvenating the immune system, although further research is required to confirm the actual health benefits.
The supplement is based on a natural metabolite called urolithin A (UA), which is produced by gut bacteria after consuming foods like pomegranates, strawberries, raspberries, or certain nuts. UA has shown promising results in promoting mitophagy, a process that removes aged or damaged mitochondria from cells and contributes to cellular health.
Animal studies have suggested that UA may have anti-aging effects and could potentially prolong lifespan and provide protection for the aging brain. These findings have led Amazentis SA to develop a purified form of UA called Mitopure, which has shown significant improvements in muscle strength in older adults in previous trials.
The latest clinical trial focused on the immune system and included 50 healthy, middle-aged adults who were randomly assigned to either take 1,000 mg of Mitopure daily or a placebo. After four weeks, participants who took the supplement showed measurable changes in immune cells in their bloodstream, with CD8āŗ T cells and natural killer cells exhibiting a ‘younger’ metabolic profile.
While these changes are promising, researchers emphasize the need for further studies to determine the long-term implications and clinical benefits of Mitopure. The supplement is set to be evaluated in a clinical trial involving cancer patients to assess its potential in complementing immunotherapy.
Overall, the findings suggest that Mitopure may help counteract age-related immune decline, but more research is required to establish its efficacy and safety for long-term use. The study was published in Nature Aging.
